DXCM News and Press, DexCom Inc. From 11/07/22

A struggling economy, rising interest rates, and negative results from high-profile corporations continue to drag the stock market down. And although medical device specialist DexCom (NASDAQ: DXCM) hasn't entirely escaped the bloodbath, the company has been doing much better in the ...

Earnings season is well on its way. And as always, some companies will report disappointing financial results and see their shares plummet. Others have already had the opposite experience: solid earnings reports that sent their shares soaring. Two such companies are DexCom (NASDAQ...

October was a good month for the stock market. The S&P 500 rose 8% after earnings season didn't turned out to be as disastrous as investors and analysts had feared. One stock that did exceptionally well last month was DexCom (NASDAQ: DXCM) , which soared by a whopping 50%. A...

Summary DexCom, Inc. had an excellent Q3, beating expectations and revising guidance. The market for diabetes remains large and growing, benefiting DexCom and its new G7 product. Despite DexCom's pure play focus and strong competitive positioning, does the valuation justify a ...

Shares of the medical device maker DexCom (NASDAQ: DXCM) shot about 50% higher in October. Unfortunately, the stock is still around 25% below the peak it reached in late 2021. Investors who have seen DexCom soar in the past only to come crashing down are justifiably nervous abou...

This November, Dexcom provides people with diabetes with an additional platform to share their stories: The #SeeDiabetes campaign advocating for access to better diabetes care. Celebrity Dexcom Warriors Patti LaBelle, Mark Andrews and Bambi Northwood-Blyth lend their voices,...

Summary Baillie Gifford’s 13F portfolio value decreased from ~$97.51B to ~$96.99B this quarter. They increased Shopify, Roblox, Zoom Video, and Twilio while reducing Albemarle Corporation and Li Auto ADR. The top three positions are Tesla Motors, Moderna, and MercadoLib...

There's good news and bad news for DexCom (NASDAQ: DXCM) shareholders so far this year. The good news is that the stock has soared nearly 30% in recent weeks. What's the bad news? DexCom's share price is still down more than 20% year to date. Some investors believe that DexCom's...

Summary Weakness in the Strategy’s consumer discretionary and technology names and underweights to several outperforming mega cap growth stocks weighed on performance relative to the benchmark. Weakness in the Strategy’s consumer discretionary and technology names an...

DexCom ( NASDAQ: DXCM ) climbed ~16% intraday Friday to reach the highest level since April after the medical device maker posted better-than- expected financials for Q3 2022, drawing favorable views on Wall Street. After the results, the analysts from Baird, Wells F...